A Phase II Study of 250-mg ZD1839 Monotherapy in Recurrent or Metastatic or Both Recurrent and Metastatic Squamous Cell Carcinoma
Phase 2 Completed
46 enrolled
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
Phase 2 Completed
70 enrolled 11 charts
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
Approved for marketing
Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Phase 2 Completed
27 enrolled 16 charts
TIDAL1
Phase 2 Terminated
32 enrolled
Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
Phase 2 Completed
44 enrolled 7 charts
Phase III Trial Of Docetaxel Versus Docetaxel Plus ZD1839 In Head And Neck Cancer
Phase 3 Terminated
270 enrolled 8 charts
ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
Phase 2 Completed
51 enrolled
Gefitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
Phase 2 Completed
60 enrolled
Cisplatin, Fluorouracil, Iressa, and Radiation Therapy Patients With Locally Advanced Head and Neck Cancer
Phase 1/2 Completed
60 enrolled 12 charts
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
Phase 1 Completed
30 enrolled
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck
Phase 2 Withdrawn
28 enrolled
ZD1839 (IRESSAâ„¢) in Combination With Docetaxel & Cisplatin in Subjects With Metastatic Head & Neck Cancer
Phase 2 Completed
36 enrolled
Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Phase 2 Completed
50 enrolled
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
Phase 1 Completed
10 enrolled
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
Phase 2 Completed
47 enrolled
The IRESSA Novel Head and Neck Chemotherapy Evaluation Study
Phase 2 Completed
64 enrolled
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Phase 2 Completed
60 enrolled
Gefitinib (Iressa) in Combo With Chemoradiation in Patients With Locally Advanced Head & Neck Cancer
Phase 1/2 Completed
40 enrolled
Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer
Phase 1/2 Terminated
29 enrolled